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Is Correlated with the Occurrence of Severe Acute
Graft-versus-Host Disease through Systemic
Release of Inflammatory Cytokines
Daihong Liu, Chenhua Yan, Lanping Xu, Yu Wang, Wei Han,
Xiaohui Zhang, Kaiyan Liu, Xiaojun HuangGraft-versus-host disease (GVHD) is a major obstacle to the success of allogeneic hematopoietic stem cell
transplantation (allo-HSCT). Although many indicators have been used to predict GVHD, the prediction of
GVHD remains very difficult. Determining how to predict the occurrence of acute GVHD (aGVHD) as
exactly as possible has been a huge challenge so far. Systemic release of inflammatory cytokines during
the conditioning regimen and early-phase post-HSCT plays a crucial role in the generation of aGVHD; addi-
tionally, the conditioning regimen causes the damage to the intestinal tract. Diarrhea is a common symptom
of intestinal tract damage during the conditioning regimen. We therefore performed a prospective study to
investigate the relationship between diarrhea related to the conditioning regimen, systemic release of inflam-
matory cytokines during the conditioning regimen and the early-phase post-HSCT, and the development of
aGVHD. This study demonstrated that duration of diarrhea was .5.5 days, with a maximal volume .8.72
mL/kg and a mean volume of diarrhea for days 23 to 0 .7.94 mL/kg were risk factors of grade II to IV
aGVHD. Diarrhea with any 1 risk factor was defined as severe diarrhea. Furthermore, this study first con-
firmed that the correlation between diarrhea and aGVHDwas related to the serum levels of tumor necrosis
factor (TNF)-a and interleukin (IL)-6 during the conditioning regimen and during the early phase after trans-
plantation. Our study demonstrated that diarrhea related to the conditioning regimen could be used as
a marker for the prediction of aGVHD and further explain the possible mechanism underlying the linkage
described here. Therefore, for the patients with severe diarrhea related to the conditioning regimen,
low-dose glucocorticoid may be used to reduce the levels of inflammatory cytokine release by a damaged
intestinal tract, and possibly further reduce the occurrence of aGVHD. For these patients, prophylaxis of
aGVHD may be need to be adjusted individually.
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Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) is a well-established curative treatment
for patients with hematologic malignancies. However,
widespread application of allo-HSCT is impeded by
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6/j.bbmt.2010.05.001graft-versus-host disease (aGVHD). Although many
indicators have been used to predict or diagnose
aGVHD, the prediction and early diagnosis of
aGVHD remains difficult. Therefore, determining
how to predict the occurrence of aGVHDas accurately
as possible has been a huge challenge.
Many reports have already confirmed that the se-
rum levels of many inflammatory cytokines during
the conditioning regimen and early-phase posttrans-
plantation correlated with the occurrence of aGVHD,
andwere used to predict the occurrence of aGVHD. In
mice bone marrow transplantation models, the higher
serum level of tumor necrosis factor (TNF)-a post-
transplantation was associated with higher incidence
of severe aGVHD and more aGVHD-related mortal-
ity [1]. In addition, in the human body, Visentainer
et al. [2] reported serum soluble interleukin-2R1567
Table 1. Clinical Characteristics of Patients (n 5 101)
Characteristics Number of Patients (%)
Age (years) 38 (12-59)
Sex (male/female) 70/31
Underlying disease
Acute myelogenous leukemia (AML) 30 (29.7)
Acute lymphoblastic leukemia (ALL) 38 (37.6)
Chronic myelogenous leukemia
(CML)
23 (22.8)
Myelofibrosis (MF) 2 (2.0)
8P11 myeloproliferative disease 2 (2.0)
Chronic myelomonocytic
leukemia (CMML)
2 (2.0)
Myelodysplastic syndrome (MDS) 2 (2.0)
Multiple myeloma (MM) 1 (1.0)
Hodgkin disease (HD) 1 (1.0)
Conditioning regimen
Bu-based 89 (88.1)
TBI-based 12 (11.9)
Sex pair (donor-recipient)
Female-Male 31 (30.7)
Female-Female 18 (17.8)
Male-Female 13 (12.9)
Male-Male 39 (38.6)
Stem cell source*
PBSC 21
BM + PBSC 80
Pretransplant chemotherapy (yes/no) 67/34
Mucositis during chemotherapy
(yes/no)
23/78
Pretransplant albumin (g/L) 43.8 (29.1-54.4)
Graft
MNC (108/kg) 6.54 (3.65-10.68)
CD34+ (106/kg) 1.95 (0.40-5.86)
CD3+ (108/kg) 1.81 (0.41-4.76)
CD8+ (108/kg) 0.64 (0.18-3.22)
CD4+ (108/kg) 0.97 (0.17-2.52)
CD14+ (108/kg) 1.11 (0.14-2.87)
Bu indicates busulfan; TBI, total body irradiation; BM, bone marrow;
PBSC, peripheral blood stem cell; MNC mononuclear cell.
*Mobilized hematopoietic stem cells.
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to 15th week posttransplantation were significantly
higher in the group that developed aGVHD than
that in the group without aGVHD, and the levels of
TNF-a in the first week posttransplantation was sig-
nificantly higher in the patients with aGVHD. Sakata
et al. [3] suggested the plasma levels of IL-6, IL-10,
macrophage colony-stimulating factor (M-CSF), and
soluble tumor necrosis factor receptors I and II
(sTNFR-I and II) from days 0-21 posttransplantation
were significantly higher in the severe aGVHD group
compared to the mild aGVHD group (grade 0-II), and
the plasma ratio of IL-10 and sTNFR-II was linked to
the poor outcome in the patients with severe aGVHD.
Shaiegan et al. [4] found that in patients who developed
aGVHD, the serum level of IL-18 increased during
days 3-24 posttransplantation, and the serum levels
of IL-18 on day 10 posttransplantation strongly corre-
lated with the severity of aGVHD. In addition, other
researchers have also reported that patients with sig-
nificant aGVHD usually had higher levels of IL-6,
IL-8, and TNF-a between days 0 and 10 posttrans-
plantation (IL-6, TNF-a, and IL-8, P\ .05) [5]. How-
ever, the measurement of any single cytokine usually
lacks sufficient specificity and sensitivity to be useful
in a clinical setting. Furthermore, these tests are costly
and not widely available. Thus, a simple and validated
indicator to predict the occurrence of aGVHD is
greatly needed.
As described before, inflammatory cytokines re-
leased during the conditioning regimen play a crucial
role in the generation of aGVHD. In addition, the
conditioning regimen also causes damage of the gas-
trointestinal tract. Diarrhea is a common manifesta-
tion of intestinal tract damage, and is also an easy
and accurate method to measure intestinal tract dam-
age. Therefore, we hypothesized that the severity of
diarrhea related to the conditioning regimen would
be a simple marker to predict the development of
aGVHD. We performed a prospective study to deter-
mine whether the severity of diarrhea correlated with
the development of aGVHD, and investigated the pos-
sible mechanism underlying the correlation between
diarrhea and aGVHD.PATIENTS AND METHODS
Patients and Data
One hundred one consecutive patients receiving
HLA-matched sibling HSCT between 2006 and 2007
at the Peking University Institute of Hematology were
included in this study. The characteristics of these
patients are shown inTable 1. Informed consent was ob-
tained fromall patients,with approval of the institutional
review board. The conditioning regimen consisted of
either busulfan (0.8 mg/kg intravenously [i.v.] every 6hours for 12 doses) followed by cyclophosphamide (Cy;
1.8 g/m2/day for 2 days) or total body irradiation (TBI)
(770 cGy daily for 1 day) followed by Cy. All patients re-
ceived mobilized BM cells plus peripheral blood stem
cells (PBSCs) or mobilized PBSCs only. All transplant
recipients received cyclosporine A (CsA), mycopheno-
late mofetil (MMF), and short-term methotrexate
(MTX) for the prophylaxis of aGVHD. The dosage of
CsAwas 2.5mg/kg/day, i.v. from day29.MMFwas ad-
ministered orally, 0.5 g every 12 hours from day 29 to
engraftment.Thedosage ofMTXwas15mg/m2 admin-
istered i.v. on day11, and 10mg/m2 ondays13 and16.
All patients were hospitalized in rooms with high-
efficiency particle-arresting (HEPA) air filters, and all
received antibiotic prophylaxis with oral orfloxacin,
sulfamethoxazole, fluconazole, and acyclovir.Diagnosis and Treatment of aGVHD
The diagnosis and grading of GVHD was done ac-
cording to published criteria [6]. Patients were assigned
as either having significant aGVHD (grade II to IV) or
not having significant aGVHD (none or grade I).
Biol Blood Marrow Transplant 16:1567-1575, 2010 1569Diarrhea during the Conditioning RegimenaGVHD of grade II or higher was treated with methyl-
prednisolone (MP) or MTX. MP was administered i.v.
at a dose of 1-2 mg/kg/day for at least 3 days. MTX
was administered intravenously at a dose of 5 or 10
mg, repeated at days 3 or 4 and day 8 after the first
dose, and then at a weekly interval, until the patients
showed a complete or partial response, treatment
failure, or intolerable side effects [7].When therewas in-
adequate or no response to primary therapy, anti-Tac
monoclonal antibody (Daclizumab; Roche, Basel, Swit-
zerland) was administered.Diarrhea Related to the Conditioning Regimen
Diarrhea was defined as stool volume .200 g/day,
stool frequency .3/day, and excessive watery evacua-
tionsof fecalmaterial.Diarrhea related to the condition-
ing regimen was defined as diarrhea that developed
during the conditioning regimen and from day 0 to
110 after transplantation [8], and negative stool patho-
genic examination results for Clostridium difficile infec-
tions, as well as for bacteria and fungi cultures. If the
patients developed diarrhea related to the conditioning
regimen, the sum of the volume, the mean volume,
and the maximum volume during the period (from
days 210 to 110), as well as the mean volume during
4 equivalent subdivisions of the period (28 to 24
days, 23 to 0 days, 11 to 15 days, and 16 to 110
days) were all recorded. Considering the influence of
the weight in the patients with different ages, diarrhea
volume was evaluated as mL/kg in this study.Evaluation of Donor Engraftment
Engraftment was defined as the first of 3 consecu-
tive days with an absolute neutrophil count (ANC)
.0.5  109/L after transplantation. Platelet engraft-
ment was defined as maintenance of a platelet count
.20 109/L for 7 consecutive days or a platelet count
.50  109/L for 3 consecutive days after transplanta-
tion. Donor engraftment was determined by at least 2
of the 3 methods: DNA-based HLA typing, DNA
fingerprinting of short tandem-repeats, and chromo-
somal fluorescein in situ hybridization (FISH).Measurement of Cytokines
Of the 101 patients, serum samples from 50 con-
secutive patients were collected before HSCT, on
the day of the transplant, and every week up to the
third week after HSCT and stored at 280C. ELISA
was used to measure the serum concentrations of IL-6
(Sunbio, Beijing, China) and TNF-a (Sunbio, Beijing,
China). All assays were performed according to the
manufacturers’ instructions at Sunbio Laboratory
(Beijing, China).Statistical Analysis
Themajor statistical aimof this studywas to identify
factors associated with grade II to IV aGVHD after
transplantation through day1100. Patients who devel-
oped aGVHD or who died because of the causes of
transplant-related complications and relapse were cen-
sored at the time of onset of aGVHD and at the time
of death, respectively. Influence factors were selected
on the basis of cross tabulations, nonparametric tests,
and subsequent logistic regressionmodeling.Univariate
analysis was performed using chi-square statistics and
Mann-Whitney U statistics where appropriate. Multi-
variate analyses were performed using logistic regres-
sion models [9]. The final multivariate models were
built using a backward stepwise model selection ap-
proach. The Youden Index [10] was used to determine
the cutoff value of continuous variables. A receiver oper-
ator characteristics (ROC) curve was used to evaluate
the diagnostic value of the risk factor. All potential inter-
acting variables were tested, screened out, and extracted
from the analysis. Overall survival (OS) was measured
from the day of HSCT (day 0) to death because of any
causes, and treatment-related mortality (TRM) was de-
fined as patient death because of any causes other than
relapse. Cumulative incidence of aGVHD, OS, and
TRM were plotted according to the Kaplan-Meier
method and compared using the log-rank test [11].
The endpoint of follow-up for all surviving patients
was September 30, 2009 (the median follow-up period
was 32 months). All reported P values with a 2-sided
P value\.05 were determined to be significant.RESULTS
aGVHD
All patients achieved a sustained and stable donor
engraftment. Among the 101 patients, 21 (20.8%) pa-
tients developed 30 episodes of aGVHD. Among the
21 that developed aGVHD, 9 (30.0%) were grade I,
11 (36.7%) were grade II, 7 (23.3%) were grade III,
and 3 (10.0%) were grade IV. The median day of onset
of aGVHD was 145 (15-96). At 100 days after trans-
plantation, the cumulative incidence was 20.0% for
grade II to IV aGVHD, and 10.0% for grade III to IV
aGVHD. Of the 30 episodes of aGVHD, 21 episodes
were treated with MP, and 15 (71.4%) episodes were
treated successfully, whereas the 6 episodes that lacked
adequate response to the primary treatment were
subsequently administeredwith anti-CD25monoclonal
antibody. Four episodes showed improvement, but
the remaining 2 patients had exacerbated GVHD and
subsequently died. The other 9 episodes were treated
with MTX and all (100%) showed improvement
(P 5 .091).
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In 101 patients, 31 patients (30.7%) developed
diarrhea related to the conditioning regimen. The me-
dian day of onset of diarrhea was 23 (27 to 13), the
median duration was 5 (3-11) days, and the median
day of disappearance was day 21 (25 to 17). With
univariate analysis, factors that might influence the in-
cidence of diarrhea related to the conditioning regi-
men were analyzed, which included age (P 5 .118),
underlying disease (P 5 .686), conditioning regimen
(P 5 .180), pretransplant chemotherapy (P 5 .805),
mucositis during chemotherapy (P 5 .947), and the
levels of albumin (P 5 .491) before transplantation.
None of these measures was determined to be an
influence factor.
Diarrhea Can Predict the Development of
Grade II to IV aGVHD
Of the 31 patients developing diarrhea during the
conditioning regimen, 12 patients (38.7%) developed
18 episodes (58.1%) of grade II to IV aGVHD; how-
ever, of the 70 patients without diarrhea, only 4
patients developed 4 episodes of grade II to IV
aGVHD (P\ .001) (Table 2). Using univariate analy-
sis, factors that might influence the incidence of grade
II to IV aGVHD were analyzed; these included age,
sex of the patients and donors, underlying disease, con-
ditioning regimen, number of mononuclear cells
(MNC), CD341, CD31, CD81, CD41, and CD141
cells infused at transplantation, duration of diarrhea,
sum of volume, mean volume, maximal volume during
the period (from days 210 to 110), and mean volume
during 4 equivalent subdivisions of the period (28 to
24 days, 23 to 0 days, 11 to 15 days, and 16 to
110 days). On the basis of univariate analysis using
logistic regression models, the influence factors were
determined to be duration of diarrhea (P 5 .026,
odds ratio [OR] 5 2.280), maximal volume (P 5
.031, OR 5 2.019), and mean volume from day 23
to 0 (P 5 .047, OR 5 1.317). The cutoff values of
the 3 continuous variables mentioned earlier were
determined using the Youden Index, and the 3 cutoff
values were subsequently tested using logisticTable 2. The Occurrence of Diarrhea Related to the Conditioning
(n 5 101)
Total (%)
aGVHD 30/101 (29.7)
aGVHD of grade II-IV 22/101 (21.8)
Skin aGVHD 14/101 (13.9)
Skin aGVHD of grade II-IV 9/101 (8.9)
Hepatic aGVHD 8/101 (7.9)
Hepatic aGVHD of grade II-IV 5/101 (5.0)
Intestinal aGVHD 18/101 (17.8)
Intestinal aGVHD of grade II-IV 8/101 (7.9)
Median day of onset of aGVHD +45 (15-96)
aGVHD indicates acute graft-versus-host disease.regression models. Finally, duration of diarrhea .5.5
days (P 5 .012, OR 5 11.500), maximum volume
.8.72 mL/kg (P 5 .032, OR 5 6.044) and mean
volume during the period from day 23 to 0 .7.94
mL/kg (P 5 .013, OR 5 12.000) were determined to
be risk factors of grade II to IV aGVHD. If the patients
developed diarrhea related to the conditioning regi-
men and any 1 of 3 risk factors was positive, the diar-
rhea was defined as severe diarrhea; in the absence of
these criteria, the diarrhea was defined as mild diar-
rhea. During the 100-day time period following trans-
plantation, of the 21 patients with severe diarrhea, 12
(57.1%) patients developed 14 (66.7%) episodes of
aGVHD of grade II to IV, 25.0% patients with mild
diarrhea developed grade II to IV aGVHD, and
5.6% patients without diarrhea developed grade II to
IV aGVHD (P\.001). In addition, of the 21 patients
with severe diarrhea, 6 (28.6%) patients developed
10 (47.6%) episodes of aGVHD of grade III to IV,
0% patients with mild diarrhea developed grade
III to IV aGVHD, and 1.4% patients without diarrhea
developed grade III to IV aGVHD (P \.001)
(Figure 1). However, no difference was observed
among the 3 groups for the median day of onset of
aGVHD (P 5 .721).The Patients with Severe Diarrhea Were
Associated with Higher Serum
Level of IL-6 and TNF-a
Kinetic studies on IL-6 and TNF-a serum levels
revealed significant differences among the 3 groups.
In the patients with mild diarrhea or without diarrhea,
maximal IL-6 and TNF-a serum levels all occurred at
day 17; however, in the patients with severe diarrhea,
IL-6 serum levels gradually increased from day25. In
addition, the maximal TNF-a serum level occurred at
day 114 in patients with severe diarrhea. Compared
with the patients with mild diarrhea, the serum levels
of IL-6 and TNF-a from day 11 to 121 after trans-
plantation were significantly higher in the patients
with severe diarrhea (P \.05 at all time points). In
the patients with severe diarrhea, the maximal serum
levels of IL-6 and TNF-a were 63.67 pg/mL andRegimen Was Associated with the Development of aGVHD
Diarrhea (%) No Diarrhea (%) P
23/31 (74.2) 7/70 (10.0) <.001
18/31 (58.1) 4/70 (5.7) <.001
10/31 (32.3) 4/70 (5.7) .004
7/31 (22.6) 2/70 (2.9) .009
5/31 (16.1) 3/70 (4.3) .045
4/31 (12.9) 1/70 (1.4) .047
15/31 (48.4) 3/70 (4.3) <.001
7/31 (22.6) 1/70 (1.4) .003
+44 (15-93) +45 (22-96) .764
Figure 1. Cumulative incidence of aGVHD in 101 patients. Patients were divided into 3 groups according to the severity of diarrhea related to the
conditioning regimen. If the patients developed diarrhea related to the conditioning regimen, and any 1 of the 3 risk factors was positive, the diarrhea
was defined as severe diarrhea. in the absence of these criteria, the diarrhea was defined as mild diarrhea. 1* represents the P value in the patients with
severe diarrhea compared with the patients without diarrhea; 2* represents the P value in the patients with severe diarrhea compared with the patients
with mild diarrhea; 3* represents the P value in the patients with mild diarrhea compared with the patients without diarrhea.
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with mild diarrhea, the peak serum levels of IL-6 and
TNF-a were 11.72 pg/mL and 12.21 pg/mL, respec-
tively (P 5 .011 and P 5 .028, respectively). By con-
trast, there was no difference between the patients
with mild diarrhea and the patients without diarrhea
from the conditioning regimen up to day 121 post-
transplantation (P ..05 at all time points) (Figure 2).Figure 2. Kinetic analyses showing that the serum levels of IL-6 and TNF-a ar
conditioning regimen. Fifty patients were divided into 3 groups according to th
developed diarrhea related to the conditioning regimen, and any 1 of the 3 risk
wise, the diarrhea was defined as mild diarrhea. 1* represents P\.05 in the pat
2* represents P\.05 in the patients with severe diarrhea compared with theThe Patients with Grade II to IV aGVHDWere
Associated with a Higher Serum Level of IL-6
and TNF-a
In all patients developing grade II to IV aGVHD,
dynamic analyses of IL-6 and TNF-a serum levels
showed significant differences. In the patients with
grade 0 to I aGVHD, themaximal IL-6 andTNF-a se-
rum levels all occurred at day 17 posttransplantation.e associated with the occurrence and severity of diarrhea related to the
e severity of diarrhea related to the conditioning regimen. If the patients
factors was positive, the diarrhea was defined as severe diarrhea. Other-
ients with severe diarrhea compared with the patients without diarrhea;
patients with mild diarrhea.
1572 Biol Blood Marrow Transplant 16:1567-1575, 2010D. Liu et al.By contrast, in the patients with grade II to IV
aGVHD, IL-6 serum levels gradually increased from
the conditioning regimen, and the peaks of TNF-a
levels appeared at day 114 posttransplantation.
Compared with the patients with grade 0 to I aGVHD,
the serum levels of IL-6 and TNF-a from day 11 to
121 posttransplantation were all significantly higher
in the patients with grade II to IV aGVHD (P\.05
at all time points). The maximal serum levels of IL-6
and TNF-a in the patients with grade II to IV
aGVHDwere 63.89 pg/mL and 55.54 pg/mL, respec-
tively; however, in the patients with grade 0 to I
aGVHD, the maximal serum levels of IL-6 and
TNF-a were 7.24 pg/mL and 9.96 pg/mL, respec-
tively (P 5 .031 and P 5 .034, respectively). Further-
more, in the patients developing grade II to IV
aGVHD, dynamic studies of IL-6 and TNF-a serum
levels showed no differences between the patients
without diarrhea and the patients with mild diarrhea
(P ..05 at all time points). In the patients with severe
diarrhea, the kinetic analyses of IL-6 and TNF-a se-
rum levels revealed significant increases from day 11
to121 posttransplantation (P\ .05 at all time points).
The maximal IL-6 and TNF-a serum levels in the pa-
tients with severe diarrhea were much higher than that
in the patients with mild diarrhea (IL-6: 111.07 pg/mL
versus 13.60 pg/mL, P 5 .024; TNF-a: 92.25 pg/mL
versus 14.98 pg/mL, P 5 .029). In addition, in the pa-
tients with grade 0 to I aGVHD, kinetic studies of IL-6
and TNF-a serum levels still showed no differences
between the patients without diarrhea and the patients
with mild diarrhea (P ..05 at all time points), but
revealed a slight increase in the patients with severe di-
arrhea. The peaks of IL-6 and TNF-a serum levels in
the patients with severe diarrhea were slightly higher
than that in the patients with mild diarrhea (IL-6:
11.91 pg/mL versus 5.25 pg/mL, P 5 .038; TNF-a:
12.54 pg/mL versus 8.64 pg/mL, P5 .046) (Figure 3).Survival and TRM
Up to the endpoint of follow-up, 16 of 101 (15.8%)
patients died. Among those that died, 6 died of relapse,
6 died of pneumonia, 2 patients died of intestinal
aGVHD of grade IV, 1 patient died of secondary en-
graftment failure, and another died of thrombotic mi-
croangiopathy (TMA). Of the 21 patients with severe
diarrhea, 8 (38.1%) patients died after transplantation,
1 patient died of relapse, and the remainder (33.3%)
died of transplant-related complications, which in-
cluded the 3 who died of pneumonia, the 2 who died
of intestinal aGVHD, grade IV, the 1 who died of en-
graftment failure, and another who died of TMA. In
contrast, of the 10 patients with mild diarrhea, only 1
patient (10.0%) died of relapse. In addition, of the 70
patients without diarrhea, 7 patients (10.0%) died;
among those who died, 4 patients died of relapse ofunderlying malignant disease, and the other 3 patients
died of pneumonia (P\.001) (Figure 4).DISCUSSION
This study is the first to demonstrate that the cor-
relation between the severity of diarrhea related to the
conditioning regimen and the development of
aGVHD was related to the systemic release of inflam-
matory cytokines during the conditioning regimen and
early phase posttransplantation.
Many reports have already confirmed the positive
correlation between the systemic release of TNF-
a and IL-6 during the conditioning regimen and
early-phase posttransplantation, and the occurrence
of aGVHD. Holler et al. [12,13] reported that in the
patients with grade II aGVHD, the maximal serum
TNF-a levels occurred at day 120 after HSCT.
More than 90% of those patients whose serum
TNF-a levels were higher than 100 pg/mL during
the conditioning regimen developed grade II to IV
aGVHD, and\30% had long-term survival. By con-
trast, 80% of patients whose serum TNF-a levels
were\100 pg/mL survived the 80-month follow-up
period. In addition, Abdallah et al. [14] observed in
the patients with aGVHD, the maximal serum level
of IL-6 occurred at the first week posttransplantation.
About 70% of patients whose serum level of IL-6 was
up to 50 pg/mL on the first week after transplantation
developed aGVHD. Our study confirmed the positive
correlation between inflammatory cytokines and
aGVHD. However, in contrast to what was described
in previous studies, we found that between the patients
with grade II to IV aGVHD and the patients with
grade 0 to I aGVHD, kinetic analyses of inflammatory
cytokines showed significant differences. In the pa-
tients with grade II to IV aGVHD, the serum levels
of IL-6 gradually increased from the first to the third
week posttransplantation, and the peak of TNF-a se-
rum levels appeared at the second week posttransplan-
tation; however, in the patients with grade 0 to I
aGVHD, the maximal IL-6 and TNF-a serum levels
all occurred at the first week posttransplantation.
Many researchers have already demonstrated the
presence of higher levels of TNF-a and IL-6 both in
serum and colonic tissue from the patients with inflam-
matory bowel disease (IBD), and have also suggested
a close correlation between the degree of mucosal dam-
age and the level of cytokines. Reinecker et al. [15] sug-
gested the spontaneous secretion ofTNF-a and IL-6 by
macrophages isolated fromnormalmucosawas very low
(6 pg/mL and 57 pg/mL, respectively), whereas the
secretion of TNF-a and IL-6 by macrophages isolated
frommicroscopically noninvolved and involvedmucosa
increased significantly (TNF-a: 19 pg/mL versus 104
mg/mL, IL-6: 326 pg/mL versus 5885 pg/mL, respec-
tively). Furthermore, Leon et al. [16] confirmed that
Figure 3. Kinetic analyses showing that the serum levels of IL-6 and TNF-a are associated with the occurrence of aGVHD of grade II to IV. (A, B) Fifty
patients were divided into 2 groups according to the severity of aGVHD. (C–F) Fifty patients were divided into 3 groups according to the severity of
diarrhea related to the conditioning regimen. If the patients developed diarrhea related to the conditioning regimen, and any 1 of the 3 risk factors was
positive, the diarrheawas defined as severe diarrhea. Otherwise, the diarrheawas defined as mild diarrhea. 1* represents P\.05 in the patients with severe
diarrhea compared with the patients without diarrhea; 2* represents P\.05 in the patients with severe diarrhea compared with the patients with mild
diarrhea.
Biol Blood Marrow Transplant 16:1567-1575, 2010 1573Diarrhea during the Conditioning Regimeninvolved mucosa isolated from patients with IBD dis-
played high expressions of TNF-a and IL-6, and that
the expression of these 2 cytokines directly correlated
to the expressions of various markers involved in the
control ofmucosal damage such as inducible nitric oxide
synthase (iNOS), apoptosis-relatedmoleculeGranzyme
B (GZNB), and matrix metalloproteinase-3 (MMP-3).
In addition to the high levels of TNF-a and IL-6 in
patients with IBD, studies in several animal models
showed that systemic release of TNF-a and IL-6 played
a crucial role in gastrointestinal tract damage caused by
chemotherapy and irradiation [17].Moreover, in animal
models, administration of pentoxifylline, which was ca-
pable of downregulating TNF-a production, led to
a decreased incidence of macroscopic and histologic
mucositis in animals receiving chemotherapy [18]. To
date, however, the correlation between gastrointestinaltract damages and the systemic release of cytokines has
not been confirmed in the patients undergoing allo-
HSCT. In our study, we first demonstrated the positive
association between diarrhea and the serum levels of
TNF-a and IL-6 during the conditioning regimen
and the early phase after transplantation. Compared
with the patients with mild diarrhea and without
diarrhea, dynamic analysis of TNF-a and IL-6 in the
patientswith severe diarrhea revealed significant differ-
ences, and the serum levels of the 2 cytokines were
positively related to the severity of diarrhea.
Although the positive correlation between the vol-
ume of diarrhea during the conditioning regimen and
the occurrence of aGVHD was already confirmed by
Goldberg et al. [19] from Johns Hopkins Hospital, the
possible mechanism underlying this correlation has not
been verified. In this study, we first verified the relation
Figure 4. OS and TRM in 101 patients. Patients were divided into 3 groups according to the severity of diarrhea related to the conditioning regimen. If
the patients developed diarrhea related to the conditioning regimen, and any 1 of the 3 risk factors was positive, the diarrhea was defined as severe
diarrhea. Otherwise, the diarrheawas defined as mild diarrhea. 1* represents the P value in the patients with severe diarrhea compared with the patients
without diarrhea; 2* represents the P value in the patients with severe diarrhea compared with the patients with mild diarrhea; 3* represents the P value
in the patients with mild diarrhea compared with the patients without diarrhea.
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flammatory cytokines release by damaged intestinal mu-
cosa. In addition, damage in the gut may increase the
exposure to bacteria and result in increasing amounts of
lipopolysaccharide (LPS) across the damaged intestinal
mucosa and into the systemic circulation. Several reports
found that sustained growth suppression of intestinal
bacteria could reduce the risk of aGVHDafter transplan-
tation [20].Many reports using animal transplantmodels
have confirmedLPS, which could stimulatemacrophage
secreting TNF-a, to be a major player in the develop-
ment of aGVHD [21,22]. So the increased exposure to
bacteria and subsequent the increased amounts of LPS
across the damaged intestinal mucosa into circulation
may be another possible mechanism underlying the
correlation between gut damage and aGVHD. How-
ever, this hypothesis needs to be confirmed in the future.
In this study, we confirmed that diarrhea related to
the conditioning regimen was associated with the
occurrence of aGVHD through the systemic release of
inflammatory cytokines.The implicationof this correla-
tion would be extremely provocative, because it would
suggest that for the patients undergoing allo-HSCT,
prophylaxis of aGVHD is possibly adjusted according
to the severity of diarrhea related to the conditioning
regimen. Many reports have verified that glucocorti-
coids such as methylprednisolone and dexamethasone
could nonspecifically inhibit the production of TNF-
a and IL-6 [23,24]. Therefore, for the patients with
severe diarrhea related to the conditioning regimen,
a low dose of glucocorticoids may be used to reducethe systemic release of inflammatory cytokines during
the conditioning regimen and possibly reduce the
occurrence of aGVHD. However, these hypotheses
need to be confirmed by clinical data in the future.
In conclusion, this study is the first to demonstrate
the positive correlation between the severity of diar-
rhea related to the conditioning regimen and the de-
velopment of grade II to IV aGVHD, and that these
processes were associated with serum levels of inflam-
matory cytokines released during the conditioning
regimen and the early phase after transplantation.
This finding implies that measuring the diarrhea vol-
ume during the conditioning regimen and the early pe-
riod after transplantation may be a useful method for
predicting the occurrence of grade II to IV aGVHD
and explain the possible reason underlying the correla-
tion between diarrhea and aGVHD. Furthermore,
because of the inhibitory effects of glucocorticoids
on the production of TNF-a and IL-6, a low dose of
glucocorticoids may be used to reduce the systemic re-
lease of inflammatory cytokines and possibly reduce
the occurrence of aGVHD in patients with severe
diarrhea related to the conditioning regimen. For
these patients, prophylaxis of aGVHDmay be possible
allowing for individual adjustment.ACKNOWLEDGMENTS
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